<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00503412</url>
  </required_header>
  <id_info>
    <org_study_id>D8480C00019</org_study_id>
    <nct_id>NCT00503412</nct_id>
  </id_info>
  <brief_title>Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors</brief_title>
  <official_title>A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open, non-randomised, radiolabelled, single centre study with a total of six patients with
      solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and
      its metabolites.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2005</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary objective is to determine the rates &amp; routes of excretion of 14C radiolabelled AZD2171 in patients by assessment of concentrations of total 14C radioactivity and AZD2171 in plasma &amp; concentrations of total radioactivity in urine&amp;faeces</measure>
    <time_frame>assessed at time intervals post dose</time_frame>
  </primary_outcome>
  <enrollment type="Actual">6</enrollment>
  <condition>Advanced Solid Metastatic Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AZD2171</intervention_name>
    <description>oral 14C</description>
    <other_name>cediranib</other_name>
    <other_name>RECENTINâ„¢</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histologically confirmed metastatic tumor which is refractory to standard therapies

          -  life expectancy is 12 weeks or longer

          -  WHO performance status is 0-12

        Exclusion Criteria:

          -  radiotherapy and chemotherapy within 4 weeks before the start of the study treatment

          -  patients with a history of poorly controlled hypertension

          -  history or evidence of any medical condition that might affect gastrointestinal
             function

          -  patients that have participated in a radiolabelled study in the last 5 years
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nick Botwood, BSc, MBBS, MRCP, MFPM</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Stan Kaye, Prod</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Marsden NHS Foundation Trust</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>January 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 16, 2007</study_first_submitted>
  <study_first_submitted_qc>July 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2007</study_first_posted>
  <last_update_submitted>January 15, 2009</last_update_submitted>
  <last_update_submitted_qc>January 15, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 19, 2009</last_update_posted>
  <keyword>phase I</keyword>
  <keyword>AZD2171</keyword>
  <keyword>solid tumor</keyword>
  <keyword>metastatic tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cediranib</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

